Patients treated with the self - expanding TAVR device also reported improvement in NYHA classifications, durable improvement in hemodynamic
valve performance, and low rates of moderate or severe
aortic insufficiency.
Among the 50 trials, 30 were primary prevention trials (general populations, smokers and workers exposed to asbestos, patients with oesophageal dysplasia, male physicians, patients with non-melanoma skin cancer, postmenopausal women, patients undergoing chronic haemodialysis, patients with end stage renal disease, ambulatory elderly women with vitamin D
insufficiency, patients with chronic renal failure, older people with femoral neck fractures, patients with diabetes mellitus, elderly women with a low serum 25 - hydroxyvitamin D concentration, health professionals, people with a high fasting plasma total homocysteine concentration, or kidney transplant recipients), and 20 were secondary prevention trials (patients with cardiovascular disease, coronary heart disease, acute myocardial infarction, unstable angina, transient ischaemic attack, stroke, angiographically proved coronary atherosclerosis, vascular disease, or
aortic valve stenosis).